Sienna Gestion Raises Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sienna Gestion boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,036 shares of the medical equipment provider’s stock after acquiring an additional 853 shares during the quarter. Sienna Gestion’s holdings in Intuitive Surgical were worth $7,575,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of ISRG. Capital Research Global Investors purchased a new position in Intuitive Surgical during the 1st quarter worth $374,390,000. Coatue Management LLC increased its position in Intuitive Surgical by 65.7% during the 4th quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after purchasing an additional 516,054 shares during the period. Vanguard Group Inc. raised its holdings in shares of Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after purchasing an additional 493,126 shares in the last quarter. Edgewood Management LLC raised its holdings in shares of Intuitive Surgical by 7.9% in the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after purchasing an additional 374,667 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Intuitive Surgical by 51.2% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after purchasing an additional 302,382 shares during the period. Institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the topic of several research reports. Piper Sandler lifted their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Morgan Stanley upped their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Truist Financial lifted their target price on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Citigroup boosted their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Finally, The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Stock Down 0.3 %

Shares of NASDAQ:ISRG opened at $482.09 on Thursday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.18. The stock has a market cap of $171.00 billion, a price-to-earnings ratio of 87.02, a PEG ratio of 5.41 and a beta of 1.39. The business has a 50-day moving average price of $466.24 and a 200-day moving average price of $423.80.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 EPS. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In related news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now owns 12,275 shares in the company, valued at $5,441,507.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,120 shares of company stock worth $25,528,753. Insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.